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Cryo-EM structure of cardiac amyloid ﬁbrils from
an immunoglobulin light chain AL amyloidosis
patient
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Giovanni Palladini3, Giampaolo Merlini3, Stefano Ricagno 1 & Martino Bolognesi 1,2
Systemic light chain amyloidosis (AL) is a life-threatening disease caused by aggregation and
deposition of monoclonal immunoglobulin light chains (LC) in target organs. Severity of heart
involvement is the most important factor determining prognosis. Here, we report the 4.0 Å
resolution cryo-electron microscopy map and molecular model of amyloid ﬁbrils extracted
from the heart of an AL amyloidosis patient with severe amyloid cardiomyopathy. The helical
ﬁbrils are composed of a single protoﬁlament, showing typical 4.9 Å stacking and cross-β
architecture. Two distinct polypeptide stretches (total of 77 residues) from the LC variable
domain (Vl) ﬁt the ﬁbril density. Despite Vl high sequence variability, residues stabilizing the
ﬁbril core are conserved through different cardiotoxic Vl, highlighting structural motifs that
may be common to misfolding-prone LCs. Our data shed light on the architecture of LC
amyloids, correlate amino acid sequences with ﬁbril assembly, providing the grounds for
development of innovative medicines.
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Light chain amyloidosis (AL), with an incidence of about 10new cases per million-persons/year, is currently the mostcommon systemic form of amyloidosis in Western coun-
tries1. The disease is associated with the presence of a plasma cell
clone, and is caused by extracellular deposition of misfolding-
prone monoclonal immunoglobulin light chains (LC), trans-
ported to target organs through blood. Deposition of amyloid
ﬁbrils is associated with dysfunction of affected organs. The
amino acid sequence of each patient’s monoclonal LC is virtually
unique, as a consequence of immunoglobulin germline genes
rearrangement and somatic hypermutation. Fibril deposition in
AL is widespread, and can target different organs; heart invol-
vement dramatically worsens patients’ prognosis2–4. Much
research is currently being devoted to deﬁning the molecular
bases of amyloid cardiomyopathy5–7, to hinder ﬁbrillogenesis8
and cell damage5,9,10.
LC subunits (ca. 215 residues) consist of two β-sandwich
domains, each hosting a disulﬁde bridge: the highly variable N-
terminal domain (Vl, ca. 105 residues), a short joining region (Jl),
and the C-terminal constant domain (Cl)6,11. Both full-length LCs
and isolated Vl domains are typical components of the deposited
ﬁbrils;12,13 nonetheless, the mechanisms promoting aggregation
in vivo remain unclear. Progress in understanding LC aggregation
is hampered by lack of structural insight on AL ﬁbrils, only low-
resolution characterization of LC ﬁbrils being available to
date14,15.
Cryo-EM is currently the ﬁrst-choice method for the structural
analysis of amyloids16–20. Notably, in the few studies reported to
date, the protein hosted within the ﬁbril was shown to adopt
composite folds, compatible with, but not fully predictable from,
ﬁbril models based on short peptides21. Moreover, whether
samples prepared in vitro or in model systems truly represent the
ﬁbril structures accumulated in patients remains an open ques-
tion. Recent structural work on Tau protein ﬁbrils well demon-
strated that the same polypeptide chain can assume different folds
within the ﬁbrils16,17, and that in vitro grown ﬁbrils may not
recapitulate the structural features observed in patient deposits22.
One further question concerns systemic amyloidosis, where the
involved amyloidogenic proteins are typically natively folded
under physiologic conditions. It is in fact unclear whether
natively folded proteins need to unfold completely before re-
assembly into cross-β structure, but also whether the native and
ﬁbril folds should bear any structural resemblance. Thus, it can be
argued that structures of ﬁbrils grown under denaturing condi-
tions, and perhaps in animal models, may not completely address
features present in patients’ amyloids20,23.
The above considerations prompted us to focus our studies on
the characterization of patient-derived amyloid ﬁbrils. Here we
present the cryo-EM structure, at 4.0 Å overall resolution, of
ex vivo LC ﬁbrils extracted from the heart of a patient affected by
severe AL cardiac amyloidosis. We show that the ex vivo ﬁbrils
are composed of an asymmetric protoﬁlament hosting 77 residues
from the LC Vl domain, coupled to two low-order regions that
comprise about one-third of the Vl domain and portions of the Cl
domain. Consideration of proteolytic patterns, ﬁbril structural
motifs, and of amino acid sequences suggests mechanisms for
aggregation and ﬁbril elongation in AL amyloidosis.
Results and Discussion
Characterization of amyloid deposits in AL amyloidosis. In
order to explore the structural organization of natural amyloid
ﬁbrils, we extracted and characterized ex vivo amyloid aggregates
from the affected heart tissue. Speciﬁcally, ﬁbrils were isolated
from left ventricle specimens acquired during autopsy from a
male patient affected by AL λ amyloidosis, with severe amyloid
cardiomyopathy. Microscopic analysis of cardiac tissue showed
extensive extracellular amyloid accumulation (Fig. 1a, b). The
monoclonal amyloidogenic LC responsible for such deposits,
labeled AL55, was sequenced from its coding mRNA from bone
marrow plasma cells; AL55 is of λ isotype and belongs to the
IGLV6-57 germline gene, which is overrepresented in the reper-
toire of amyloidogenic LCs, compared to the polyclonal
repertoire24,25.
The molecular composition of the isolated ﬁbrils was analyzed
through a proteomic approach, based on two-dimensional
polyacrylamide gel electrophoresis (2D-PAGE) followed by
nano-liquid chromatography tandem mass spectrometry (nLC-
MS/MS) analysis of excised protein spots. In agreement with
previous observations12,13, AL55 ﬁbrils are composed of a
heterogeneous population of LC proteoforms and N-terminal
LC fragments (Fig. 1c, Supplementary Figure 1). Besides species
corresponding to the intact AL55, as commonly observed in AL λ
deposits13, chain fragments whose molecular weight is lower than
the full-length LC are predominant in the ﬁbrils; all host a
complete Vl domain and extend through regions of the Cl
domain. After tryptic digestion of the protein spots, our nLC-MS/
MS data allowed to identify AL55 fragments extending to residues
129, 134, or 150, i.e. to residues located at the distal ends of the
ﬁrst or of the third β-strands in the Cl domain, respectively
(Supplementary Figure 1d–f). Low molecular weight fragments
are resistant to ﬁbril limited proteolysis in vitro (Supplementary
Figure 1c); in contrast, degradation of the longer proteoforms is
observed, suggesting protection or burial of the Vl domain within
the assembled ﬁbril.
Cryo-EM structure of the AL55 ﬁbrils. Contrary to previous
reports14, our negative staining electron microscopy and cryo-EM
analyses of freshly extracted AL55 amyloid material revealed no
polymorphs (Fig. 1d, Supplementary Figure 2). AL55 ﬁbrils dis-
play a helical pitch of 1070 ± 30 Å and 80–175 Å width range
(Supplementary Figure 2). Absence of two symmetric protoﬁla-
ments is evident from inspection of the ﬁbrils in raw micro-
graphs, and in images obtained by reference-free 2D classiﬁcation
of segments comprising an entire helical pitch (Fig. 1d, Supple-
mentary Figure 2). 2D class averages of vitriﬁed AL55 ﬁbrils,
where β-strands are clearly resolved, suggest the presence of a
highly ordered core surrounded by low-order regions (Fig. 1e,
Supplementary Figure 2). Cryo-EM 3D reconstruction of AL55
ﬁbrils resulted in a map at overall resolution of 4.0 Å, in which the
cross-β structure was clearly resolved (Fig. 2, Supplementary
Figure 3, Supplementary Table 2). Consistent with the 2D ana-
lyses, the AL55 density map showed a ﬁbril core whose con-
secutive β-strand rungs are related by helical symmetry, with a
rise of 4.9 Å, a twist of approximately –1.6°, and two low-order
outer regions.
For each LC subunit deposited along the ﬁbril axis, the inner
structured core is divided into two segments: the central part of
the density displays a “snail-shell” trace that is surrounded by a
second, “C-shaped”, extended polypeptide stretch (Fig. 2a). The
two regions are spatially contiguous but not directly connected by
interpretable density, indicating that two distinct LC segments
build the ﬁbril core. Several bulky side-chains visible in the map,
together with the Cys22–Cys91 disulﬁde bridge, supported chain
tracing and modeling for 77 residues of AL55 Vl. As a result, the
ﬁrst N-terminal 37 residues map into the internal snail-shell
region, while the outer C-shaped stretch hosts residues 66–105
(Fig. 2d). Individual LC subunits assemble with a parallel β-sheet
topology along the ﬁbril elongation axis, i.e. along the inter-
subunit H-bonding direction. Each subunit presents nine β-
strands; β1–β5 belong to the snail-shell region, and β6–β9 pack
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around it in the C-shaped stretch (Fig. 2f). In particular, strands
β1, β3, β5, and β6 face each other and tightly pack their side
chains together, while β4, β7, and β9 form a second contact
region of lower side chain packing density.
As previously reported for other amyloid ﬁbril structures16–18,20,26,
the β1–β5 modeled strands do not lay in a planar arrangement
within the ﬁbril; rather, the snail-shell region adopts a β-helix-like
structure. In particular, the polypeptide chain of LC subunit i,
whose N-terminus rests on plane i, rises twice along the ﬁbril axis,
at residues Pro14 (to i+1 level) and at Trp36 (to i+2 level). As a
result, and looking along the opposite ﬁbril axis direction, the side
chains from subunit i strand β1 pack against the C-terminal
residues of subunit i−2 (Fig. 3a). On the contrary, the C-shaped
region (β6–β9) lays essentially in a plane; given that it is
covalently bound to the snail-shell region through the
Cys22–Cys91 disulﬁde bond, this segment in subunit i is located
at the i+1 level (Fig. 3a). Such overall assembly produces ﬁbril
ends that are not ﬂat. Thus, analogously to what has been
discussed for amyloid-β (Aβ1–42) ﬁbrils18, the two ﬁbril ends
present a groove and a ridge (Fig. 3b, c), both of which expose
highly hydrophobic patches (β1–β3 interface). Conceivably, the
edge β1-strand of a natively folded LC could be recruited through
interaction with the hydrophobic groove/ridge of a growing ﬁbril,
promoting unfolding and association of a new subunit.
AL55 unfolding is an obligate step for amyloid formation.
Figure 4 compares a molecular model of the natively folded AL55
Vl, displaying the typical immunoglobulin β-sandwich domain,
with the ﬁbril structure of AL55 Vl (Fig. 4a, c), and allows a few
general considerations. Native AL55 Vl displays a compact
domain composed of two antiparallel β-sheets; conversely, in
ﬁbrils, 77 Vl residues adopt a relatively planar organization
devoid of intramolecular β-sheet-like interactions. The natively
folded Vl domain is fully structured for ca.105 residues, while
about one-third of the ﬁbril Vl (residues 38–65) fall in a poorly
structured region. Moreover, although both the native and the
ﬁbril structures essentially consist of β-strands and loops, the
locations, number, and extensions of such structures are mark-
edly different in the two states (Fig. 4b). Essentially none of the
side-chain interactions present in the tertiary structure of native
AL55 are conserved in the ﬁbril. Two salt bridges stabilize the
ﬁbril core: expectedly, Lys82–Glu84 is also present the native
folded state, while the Lys16–Asp95 salt bridge links residues that
are 40 Å apart in the folded AL55 Vl domain. Similar con-
siderations hold for hydrophobic contacts: none of the hydro-
phobic contacts observed in the ﬁbril (Phe2–Ile20; Leu4–Leu18,
and Ile29–Leu81; Ile29–Ile78 and Ala30–Leu76) can be achieved
in the domain folded state. The above observations suggest that
in vivo major unfolding of AL55 Vl is an obligate step for amyloid
formation.
Role of the AL55 sequence in ﬁbril assembly. Overall, the
AL55 segments that build the structured ﬁbril core are char-
acterized by a few charged residues (9 out of 77), four of which
are involved in two salt bridges (Lys16–Asp95, Lys82–Glu84)
alleviating Coulombic repulsion (Fig. 5a, b). The 82–88 segment,
which comprises most of the charged residues, is detached from
the inner ﬁbril core (Fig. 5b) and may prove accessible to water
molecules. The Vl stretches predicted to be most aggregation
prone27 are all comprised in the ﬁbril core (Fig. 4b) that hosts two
hydrophobic clusters. The ﬁrst cluster builds the β1–β3 interface
(Phe2, Leu4, Leu18, Ile20), while the second is located between
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Fig. 1 Morphological and molecular characterization of AL55 ﬁbril deposits. a Myocardial tissue from patient AL55, stained with Congo red. Red-orange
stain and apple-green birefringence indicate amyloid deposits under visible (left) and under polarized light (right), respectively (magniﬁcation ×100; scale
bar 100 μm). b Immuno-electron microscopy imaging of heart tissue from patient AL55 (magniﬁcation ×6000). Extracellular amyloid ﬁbrils are visible on
the right side: the gold-conjugated secondary antibody appears as black dots. The cardiomyocyte sarcomeres are visible in the upper left corner. Scale bar:
600 nm. The squared portion is zoomed in the inset on the right. c 2D-PAGE analysis of puriﬁed AL55 LC ﬁbrils (inset from Supplementary Information
Fig. 1b, left panel), showing the spots identiﬁed by MS as AL55 LC fragments (framed). These encompass the full Vl and variable portions of Cl (MS
sequence coverage ranges from aa 1–129 to aa 1–150). Low and high MW fragments comprise residues from the N-terminus to residue 129, and to 150,
respectively. d Representative cryo-EM micrograph of AL55 LC ﬁbrils; orange arrows highlight ﬁbril cross-overs. e Reference-free 2D class averages of
AL55 ﬁbril showing distinct cross-β staggering (green arrows)
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09133-w ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1269 | https://doi.org/10.1038/s41467-019-09133-w |www.nature.com/naturecommunications 3
the β4–β5 turn and β6–β7 (Ile29, Leu76, Ile78, Leu81) (Fig. 5a),
and includes the disulﬁde bond linking β4 to β7. The two prolyl
residues in the ﬁbril core (Pro7 and Pro14) help forming the β1–
β2 and β2–β3 turns, respectively. In the native Vl immunoglo-
bulin fold Pro7 is located at the center of the edge β1-strand that
is bulged; notably, such bulged edge strands are held to protect
against amyloid aggregation28. Nevertheless, in the AL55 ﬁbril
core Pro7 conveniently accommodates in the β1–β2 turn.
Besides the structured core region, as mentioned above (Fig. 1e,
and Supplementary Figure 2), AL55 ﬁbrils present two areas of
lower order: the ﬁrst falls between residues 37 and 66 of the
structured segments (Fig. 2). As limited proteolysis suggests that
the whole Vl domain is protected in the ﬁbril core, we postulate
that the 38–65 polypeptide ﬁlls the low-order region adjacent to
residues 37 and 66. The 38–65 sequence hosts residues with low β
propensity (four Pro and three Gly) and seven charged residues,
which might prevent the formation of regular β-structures once
out of the folded immunoglobulin domain context. The second
poorly structured zone surrounds the last core modeled residue
(Gly105) (Fig. 2d). nLC-MS/MS analysis shows that the ﬁbrils
contain portions of the Cl domain (that follow beyond Gly105 in
the intact LC). Similar to the 38–65 low-order region described
above, the portion of AL55 downstream of the three consecutive
Gly residues terminating the structured ﬁbril core hosts residues
with low aggregation propensity, such as four Pro and four
charged residues that may trigger the onset of this low-order
region. Moreover, heterogeneity in extension of the AL55 C-
terminal region can also contribute to packing defects and
conformational variability within the ﬁbril, thus negatively
affecting the local cryo-EM density observed (Fig. 2d).
LC sequence and ﬁbril assembly. AL55 sequence belongs to the
λ6 subgroup, and in particular to the IGLV6-57 germline gene,
which is expressed in about 2% of in bone marrow plasma cells
expressing λ LC25, but makes up to 18% of all the monoclonal λ
proteins responsible for AL amyloidosis24. Given the relevance of
such subgroup in AL pathogenesis, several previous studies have
analyzed proteins belonging to the IGLV6–57 segment, their
aggregation propensity and the role of speciﬁc positions in tuning
protein stability and amyloidogenicity29. In particular, the inter-
action between residues Phe2 and Arg25 highly stabilizes the Vl
native fold, while amino acid variations in one of the two posi-
tions increases the overall aggregation propensity30,31. Gly at site
25, as occurring in AL55, is reported to facilitate amyloid
formation31.
The LC ﬁbril model, here presented, shows that two AL55
hypervariable complementarity determining regions (CDR)
contribute to the structured ﬁbril core. CDR1 (Thr23-Gln35)
spans strands β3 through β4; CDR3 (Gln92-Val101) falls at the
C-end of the modeled ﬁbril core. Such observations highlight
sequence variability of Vl domains as a key factor not only for
protein instability and aggregation propensity, but also for the
molecular interactions that stabilize ﬁbril assembly. Thus,
questions arise on how common the ﬁbril architecture here
reported might be for AL deposits due to LCs other than AL55.
Structure-based considerations can be drawn.
Firstly, AL55 solubilized ﬁbrils provide a typical pattern in 2D-
PAGE observed in the other solubilized AL deposits from
patients13. The fragments of molecular weight lower than the full-
length LC are highly abundant and consist of the Vl domain, with
or without a short stretch of Cl domain; even the shorter
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Fig. 2 Structure of AL55 amyloid ﬁbrils. a–c Orthogonal views of the post-processed 3D reconstruction at overall resolution of 4.0 Å (FSC= 0.143).
d Overview of the AL55 ﬁbril cryo-EM map covering the structured ﬁbril core region (blue). Cross-sectional EM densities of sharpened, 4.0 Å (blue) and
unsharpened, 4.5 Å low-pass ﬁltered (gray) reconstructions. e Atomic model of AL55 (residues 1–37 and 66–105) superimposed on a cross-section of the
EM density map. f Ribbon representation of the ﬁbril structured core, rainbow colored. Four stacks (subunits) in the typical cross-β arrangement are shown
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fragments always contain the LC N-terminal region13, strongly
suggesting that the Vl domain is constantly required to build the
ﬁbril core. To assess whether other LCs may be compatible with
the ﬁbril architecture here reported, AL55 sequence was aligned
with eight diverse cardiotoxic λ LCs (Fig. 5c) previously
reported6. Despite sequence variability, the residues that appear
to play structuring roles in AL55 ﬁbrils are conserved or
conservatively mutated. An N-terminal stretch of hydrophobic
residues, building the ﬁbril inner β1-strand, is present in all
sequences (Fig. 5a, c). Frequently, an extra prolyl residue (Pro8)
can be found, which would be located in the β1–β2 turn, not
impairing the ﬁbril fold observed for AL55. Indeed, previous
evidence showed that the His8→Pro mutant in the Vl domain
belonging to the IGLV6–57 slowed but did not abrogate ﬁbril
formation32. Gly15, which in the AL55 ﬁbril core adopts a
conformation unfavorable for other amino acids, is conserved in
all sequences. The conserved disulﬁde bond is a strong structural
restrain. The two hydrophobic clusters stabilizing the AL55 ﬁbrils
can be assembled in all other eight λ LCs. Moreover, several
aromatic residues that stabilize the ﬁbril through inter-subunit
stacking interactions, and the (82–88) segment comprising
charged residues, are present in all sequences (Fig. 5a, c). A
recent ssNMR model of in vitro ﬁbrils formed by a Vl belonging
to the IGLV6–57 gene segment and with only 12 mutations when
compared to AL55 sequence, shows several structural analogies.
Even though the N-terminal stretch is predicted partially ﬂexible,
both the reported polymorphs display two ordered regions
(residues 20–45 and 65–103) with parallel arrangement and a
disordered region spanning residues 45–60 (ref. 33).
Hence, overall, while the sequence variability observed in Vl
domains might result in different ﬁbril structural arrangements,
as observed for example for different isoforms of the Tau
protein16,17, nevertheless, our results strongly suggest that the
structural motifs observed in the AL55 ﬁbril architecture are
compatible with the assembly of amyloid deposit from different
LCs, opening the way to an innovative and targeted molecular
characterizations of AL amyloidosis.
Finally, some considerations on the role of proteolysis in AL
amyloidosis may be drawn. Although the presence of multiple
N-terminal LC fragments is a universal ﬁnding in AL amyloid
ﬁbrils, it is however unclear whether proteolysis releases
amyloidogenic LC fragments, which then assemble into ﬁbril
deposits, or whether proteolysis occurs after amyloid formation.
Recent reports suggest that susceptibility to proteolysis is
distinctive for amyloidogenic LCs6,34,35. Our nLC-MS/MS
analysis of AL55 ﬁbrils allowed the identiﬁcation of peptides
from LC fragments extending to the distal ends of the ﬁrst or of
the third Cl domain strands. These protein regions are solvent
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Fig. 3 Fibril subunits are not planar. a A horizontal plane (perpendicular to
the ﬁbril elongation axis) is added to this ribbon representation of the ﬁbril
core to highlight the raise of each subunit at the end of the β2 strand
(Pro15) and of β5 (Trp36), respectively. b, c A structural view of the ﬁbril
ends: the inner core concave region (groove) is shown in b; the inner core
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Fig. 4 Comparison of native and ﬁbril AL55 structures. a Ribbon representation of AL55 Vl domain native structure (model). The ordered and disordered
regions in the structure of the ﬁbril core are in yellow and blue, respectively. b Sequence of AL55 Vl domain: scheme of the secondary structure elements of
the natively folded LC (N, blue), and of the ﬁbril assembly (F, yellow), respectively; dashed lines correspond to residues not-modeled in the EM density.
Residues are colored according to their intrinsic aggregation propensities, as deﬁned by CamSol27 (high, in red; low, in black; very low in blue). c Ribbon
representation of the AL55 Vl domain ﬁbril structure
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09133-w ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:1269 | https://doi.org/10.1038/s41467-019-09133-w |www.nature.com/naturecommunications 5
exposed in the native LC domain structure (Supplementary
Figure 1), thus proteolysis could feasibly take place when the LC
chains are natively folded. In turn, such cleavages may well
destabilize (i.e. start unfolding of) the Cl domain, whose
structural integrity is known to play a stabilizing role for the
full LCs36. The overall structure of the AL55 ﬁbrils on the other
hand, shows that the Cl domain is not protected in the mature
ﬁbrils, thus it might be completely removed by proteolysis
occurring on ﬁbril deposits. Taken together, the above
structural and biophysical considerations allow speculating
that LC proteolysis may occur to a large extent before
aggregation.
In summary, the data here reported present a cryo-EM
characterization of ex vivo ﬁbrils from a patient affected by the
most common systemic form of amyloidosis. Together with the
recent work on the Tau protein16,17, to date, this is the only
structural analysis of ﬁbrils carried over on materials directly
extracted from human tissue under pathologic conditions. The
data and associated considerations help shedding light on some
of the basic molecular aspects of AL amyloidosis and, more in
general, of systemic amyloidoses. AL55 ﬁbrils present an
asymmetric single protoﬁlament; 77 residues belonging exclu-
sively to the AL55 Vl domain are required to build the
structured core, and to extend the ﬁbril through intermolecular
hydrogen bonds and hydrophobic contacts. Despite the high
sequence variability typical of Vl domains, the amino acid
sequences of other amyloidogenic (cardiotoxic) LCs are
compatible with the ﬁbril main structural motifs here identiﬁed.
Having shed light on the structure of ex vivo ﬁbrils that result
from an otherwise natively folded protein, our results, as a
whole, support the concept that LC unfolding is needed along
the aggregation pathway in AL disease. In this context, we
propose a major role for proteolysis in triggering the LC
amyloid aggregation process.
Methods
Fibril extraction from heart. Heart tissue (left ventricle) was acquired during
autopsy from a patient (herein indicated as patient AL55) affected by systemic AL λ
amyloidosis, whose autopsy examination showed Congo red positivity in heart,
kidney, lung, liver, pancreas, and spleen. The patient died of acute bronchopneu-
monia with alveolar damage. Tissue was stored frozen (−80 °C) without ﬁxation
until use. The diagnosis of amyloidosis had been made 4 years earlier; the main
clinical features are described in Supplementary Table 1. The patient was treated
with oral melphalan and dexametasone37–39, with achievement of complete
hematological remission and organ response. Six months before the patient’s death,
reappearance of the serum monoclonal component was documented, but no
therapy was started due to the stability of organ damage. Bone marrow had been
withdrawn from the same patient during the routine diagnostic procedures, upon
acquisition of the informed consent for storage and use of samples for research
purpose. This study has been approved by the Ethical Committee of Fondazione
IRCCS Policlinico San Matteo and was performed in accordance with the
Declaration of Helsinki. The presence of amyloid deposits was evaluated by Congo
red staining analysis under polarized light and by electron microscopy. Amyloid
typing was conﬁrmed by immuno-electron microscopy40. Organ involvement was
deﬁned according to international criteria41. Baseline clinical and demographic
information has been collected (Extended Data Table 1). Fibrils were extracted as
described by Annamalai et al.42. Brieﬂy, 0.5 g of tissue were cut in small pieces and
repeatedly washed in Tris calcium buffer (20 mM Tris, 140 mM NaCl, 2 mM CaCl2,
pH 8.0; each washing step was followed by centrifugation at 3100g at 4 °C). Tissue
was then digested overnight with Clostridium histolyticum collagenase (Sigma
Aldrich, Saint Louis, MO, USA) (5 mg/ml in Tris calcium buffer at 37 °C). The
material was centrifuged at 3100g for 30 min at 4 °C. The pellet was manually
homogenized with a glass Potter pellet pestle in 1 ml of Tris EDTA buffer (20 mM
Tris, 140 mM NaCl, 10 mM EDTA, pH 8.0). The homogenate was centrifuged for
5 min at 3100g at 4 °C. This step was performed for 10 times overall. The remaining
tissue pellet was homogenized with a glass Potter pestle in 1 ml of ice-cold water.
The homogenate was centrifuged for 5 min at 3100g at 4 °C and the supernatant
was stored. This step was repeated six more times, without pooling supernatants.
The cryo-EM and proteomic analyses were performed on fraction 3. Immediately
after protocol completion complete protease inhibitor cocktail (Roche, Basel,
Switzerland) was added to ﬁbrils (with the exception of ﬁbrils destined for limited
proteolysis experiments), and the sample tubes were stored on ice until analysis.
cDNA sequencing of monoclonal free LC. Total RNA was extracted from 107
bone marrow mononuclear cells with TRIzol reagent (Life Technologies, Paisley,
United Kingdom). Monoclonal λ LC sequence was cloned by a universal inverse-
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Fig. 5 The ﬁbril assembly depends on AL55 sequence. a A 2D schematic view of the core polypeptide stretches. Residues are colored as follows: gray
hydrophobic, cyan polar, red and blue negatively and positively charged, respectively. b Stick representation of the ﬁbril core together with a surface
representation colored according to electrostatic charges. c AL55 Vl is aligned against eight previously reported LCs responsible for severe cardiac
amyloidosis; such LCs display highly diversiﬁed sequences and belong to distinct germlines6. The ﬁrst line shows only AL55 residues modeled in the map.
Residues considered particularly relevant in determining AL55 ﬁbril structured core fold are highlighted in green. Conserved residues are highlighted in
yellow. The nine LCs here aligned belong to the following germlines: AL55 IGLV6–57; H3 IGLV1–44; H6 IGLV1–51; H7 IGLV1–51; H9 IGLV2-8; H10 IGLV1–36;
H15 IGLV6–57; H16 IGLV2–14; H18 IGLV3–19
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PCR strategy43, using primers speciﬁc for the 5′ (5′-AGTGTGGCCTTGTTGGCT
TG-3′) and 3′ (5′-GTCACGCATGAAGGGAGCAC-3′) portions of the λ LC
constant region. The germline gene of V region was deduced by sequence align-
ment with the current releases of EMBL-GenBank (https://www.ncbi.nlm.nih.gov/
genbank/), V-BASE (http://www.vbase2.org/) and IMGT (http://www.imgt.org/)
sequence directories. In order to obtain the original full-length LC sequence,
standard RT-PCR was employed using the same RNA, N-terminal monoclonal V
region primer (5′-AATTTTATGCTGACTCAGCCC-3′) and a universal Cλ car-
boxyterminal primer, corresponding to the last amino acids of the constant region
(5′-TGAACATTCTGTAGGGGCCAC-3′)44. After puriﬁcation of recombinant
plasmid, insert was sequenced from both sides.
Limited proteolysis. Proteins were quantiﬁed using BioRad Protein assay (Bio-
Rad, Hercules, CA, USA) after 1:4 dilution of the ﬁbril suspension with isoelec-
trofocusing (IEF) buffer (7 M urea, 2 M thiourea, 4% CHAPS, 0.1 M DTT) and
incubation for 30 min at room temperature, in order to disrupt the aggregates. For
limited proteolysis, a volume of puriﬁed ﬁbrils corresponding to 20 μg of proteins
was incubated with 0.1 μg/ml of Proteinase K (Sigma Aldrich, Saint Louis, MO,
USA), at 37 °C, in a buffer containing 10 mM Tris pH 8, 10 mM NaCl, 5 mM
CaCl2. The reaction was stopped after 1 h by dilution 1:4 (v:v) with a solution
containing 7M urea, 2 M thiourea, 4% CHAPS, 0.1 M DTT, and freezing at
−80 °C.
Two-dimensional polyacrylamide gel electrophoresis. For 2D-PAGE analysis,
25 μg of ﬁbril proteins were diluted (1:4 v:v) in IEF buffer, with addition of pI 3–10
ampholytes (Bio-Rad) to a ﬁnal concentration 0.02% v/v (ﬁnal volume ~200 µl)
and incubated for 30 min at room temperature. First and second electrophoretic
dimensions were performed using, respectively, 11 cm strips, non-linear 3–10 pH
gradient (Bio-Rad) and 8–16% polyacrylamide gradient midi format gels (Criterion
TGX gels, Bio-Rad). IPG strips were subjected to active rehydration at 50 V for
12 h. Isoelectric focusing was performed in a Bio-Rad ProteanTM IEF cell as fol-
lows: 250 V for 15 min, increase up to 8000 V over 1 h and 8000 V steady until a
total of 35,000 V–h had elapsed. Proteins were reduced and alkylated (using
iodoacetamide) between ﬁrst and second dimension. All gels were stained with
colloidal Coomassie blue (Pierce, Thermo Fisher Scientiﬁc, Waltham, MA, USA)
and imaged using a Gel Doc XR imaging system (Bio-Rad). For western blotting,
proteins were transferred onto a PVDF membrane (Bio-Rad) using a trans Blot
Turbo apparatus (Bio-Rad) and probed with polyclonal rabbit anti-human λ LCs
(Dako, Agilent, Santa Clara, CA, USA) used at a concentration of 1 μg/ml, followed
by incubation with an horseradish-peroxidase conjugated swine anti-rabbit sec-
ondary antibody (Dako).
Protein spots analysis and identiﬁcation. Protein spot excision and in-gel
digestion were performed as previously described13. Tryptic digests from each spot
were analyzed using an Eksigent nanoLC-Ultra 2D System combined with cHiPLC-
nanoﬂex system (trap-elute mode) (Eksigent, AB SCIEX Dublin, CA, USA) coupled
to Q Exactive mass spectrometer (Thermo Fisher Scientiﬁc, San Josè, CA, USA).
Brieﬂy, tryptic digests were ﬁrst loaded on the cHiPLC trap (200 µm × 500 µm
ChromXP C18-CL, 3 µm, 120 Å) and washed in isocratic mode with 0.1% aqueous
formic acid for 10 min at a ﬂow rate of 3 µl/min. The automatic switching of
cHiPLC ten-port valve then eluted the peptide mixture on a nano cHiPLC column
(75 µm × 15 cm ChromXP C18-CL, 3 µm, 120 Å), through a 40 min gradient of
5–60% acetonitrile (containing 0.1% formic acid), at a ﬂow rate of 300 nl/min. Trap
and column were maintained at 35 °C. A Q Exactive mass spectrometer was
equipped with a nanospray ionization source using a coated fused silica emitter
(New Objective, Woburn, MA, USA) (360 µm o.d./50 µm i.d.; 730 µm tip i.d.) held
at 1.9 kV. The ion transfer capillary was held at 220 °C. Full mass spectra were
acquired in positive ion mode over a 400–1600m/z range and with a resolution
setting of 70000 FWHM (@ m/z 200) with 1 microscan per second. Each full scan
was followed by seven MS/MS events, acquired at a resolution of 17,500 FWHM,
sequentially generated in a data-dependent manner on the top seven most abun-
dant isotope patterns with charge ≥2, selected with an isolation window of 2m/z,
fragmented by higher energy collisional dissociation (HCD) with normalized col-
lision energies of 30 and dynamically excluded for 30 s. Data were processed using
the Sequest HT-based search engine contained in the Thermo Scientiﬁc Proteome
Discoverer software, version 2.1. using a human protein database downloaded in
January 2018 from UNIPROT, and augmented with the sequence of AL55. The
following criteria were used for the identiﬁcation of peptide sequences and related
proteins: minimum precursor mass 400 Da, maximum precursor mass 5000 Da
(S/N ratio for peak ﬁlter 1.5); maximum missed cleavage per peptide 3; minimum
peptide length 6 amino acids; maximum peptide length 144 amino acids; tolerance
on precursor mass was set at 10 ppm and on fragment mass at 0.05 Da. Percolator
(maximum delta Cn 0.05 and maximum rank 1). Target false discovery rate was
0.01 in strict mode. Validation was based on q-value.
Electron microscopy sample preparation. Freshly extracted AL55 ﬁbrils were
ﬁrst analyzed by negative staining EM. Brieﬂy, a 4-μl droplet of sample was applied
onto a 400-mesh copper carbon-coated grids (Agar Scientiﬁc), glow discharged for
30 s at 30 mA using a GloQube system (Quorum Technologies). After 1-min
incubation, excess of sample was removed and the grid was stained with 2% (wt/v)
uranyl acetate solution, blotted dry, and imaged on a LEO 912Ab transmission
electron microscope (Zeiss) operating at 100 keV. For cryo-EM grid preparation, a
3-μl droplet of freshly extracted AL55 ﬁbrils was applied onto a glow discharged
holey carbon grids (Quantifoil R1.2/1.3, 300-mesh), incubated for 30 s, and plunge-
frozen in liquid ethane using a Vitrobot Mk IV (Thermo Fischer Scientiﬁc)
operating at 4 °C and 100% RH.
Cryo-EM data collection and image processing. In total, 1680 images of vitriﬁed
AL55 ﬁbrils were acquired on a Falcon 3EC direct electron detector (Thermo
Fischer Scientiﬁc) using a Thermo Fischer Talos Arctica transmission electron
microscope operating at 200 kV. Each image was acquired with an exposure time of
1 s and a total accumulated dose of 50 electrons per A2 equally distributed over 39
movie frames. Images were acquired at a nominal magniﬁcation of ×120,000,
corresponding to a pixel size of 0.889 Å/pixel at the specimen level, with applied
defocus values between −0.5 and −2.5 μm.
Prior to image processing, anisotropic magniﬁcation distortion was
automatically estimated using mag_distortion_estimate45. Images were corrected
for anisotropic magniﬁcation distortion (resulting in a corrected pixel size of 0.887
Å), motion-corrected and dose-weighted using MOTIONCOR2 (ref. 46). Contrast
transfer function (CTF) estimation was performed on aligned, unweighted sum
images using CTFFIND4 (ref. 47). Micrographs reporting resolution estimate of 5 Å
or better were selected for further analysis. A total of 678 selected micrographs
were imported in RELION 2.1 (refs. 48,49) for subsequent image-processing tasks.
Filaments were manually picked using RELION’s helix picker from non-dose-
weighted images. Segments were successively extracted using a box size of 320 pixel
and inter-box distance of ~10% (28.2 Å), yielding a total of 104,689 segments.
An initial reference-free 2D classiﬁcation was performed with regularization
value of T= 2 to remove segments containing ﬁlament’s termini and contaminants.
Subsequent rounds of reference-free 2D classiﬁcation were performed with
regularization value of T= 4 to select for segments contributing to averages in
which the ﬁlament’s cross-β structure was clearly visible. A total of 97,723 segments
were selected for subsequent 3D classiﬁcation and reﬁnement steps. Inspection of
the squared amplitudes of the Fourier transform of the 2D class averages displaying
the cross-β pattern showed a marked peak on the 1/(4.9 ± 0.05 Å) layer line. The
initial estimate of the helical twist was calculated from measurements of AL55
ﬁlament crossover distances in cryo-EM images (1070 ± 30 Å).
An initial 3D model was obtained using relion_helix_toolbox. The model was
low-pass ﬁltered to 60 Å and used as reference for a 3D classiﬁcation with single
class (K= 1), regularization value of T= 4 and imposing a helical rise of 4.90 Å and
a helical twist of −1.68°. The resulting 3D reconstruction was low-pass ﬁltered to
30 Å and used as a reference for subsequent rounds of 3D classiﬁcation using
multiple classes (K= 4), a regularization values of T= 10 and local optimization of
helical twist and raise parameters. For each round of classiﬁcation, segments
contributing to 3D class displaying β-strand separation along the helical axis were
selected for subsequent reconstructions. A total of 21,031 segments were used for
3D auto-reﬁne procedure using a 7 Å low-pass ﬁltered map from previous 3D
classiﬁcation, a helical z_percentage parameter of 10%, and allowing the
optimization of helical twist and rise. Finally, the reﬁned 3D reconstruction was
sharpened using RELION’s standard post-processing procedure applying a soft-
edge solvent mask and a β-factor of −106. The overall resolution estimate of the
ﬁnal map was 4.0 Å, calculated from Fourier shell correlations at 0.143. Helical
symmetry was imposed on post-processed 3D map using the relion_helix_toolbox.
Estimation of local resolution was performed using RELION 2.1. Further details are
listed in Extended Data Table 2.
Model building and reﬁnement. The initial model was prepared using Chimera50
by assembling three-residues poly-Ala fragments into the ﬁnal sharpened cryo-EM
density map. The poly-Ala model was then reﬁned using Coot and Phenix51,52.
Subsequently, each Ala residue was mutated according to consensus between the
AL55 protein sequence and ﬁnal EM map features. Residues assignment was
guided by the presence of an intramolecular disulﬁde bridge between Cys22 and
Cys91 and other visible side-chain densities. The ﬁnal model comprises AL55
residues 1–37 and 66–105. Real space reﬁnement using Phenix, with a resolution
cut-off of 4.0 Å, was performed on a ﬁbril fragment consisting of ﬁve subunits
(each one comprising the two segments 1–37 and 66–105). After each reﬁnement
stage, Coot was employed to manually adjust clashes, Ramachandran and rotamer
outliers. During the reﬁnements non-crystallographic symmetry constraints were
imposed on the ﬁve subunits overall, and also on rotamers, C-beta deviations,
Ramachandran plot, and secondary structure restraints. β-Sheet restraints were
initially imposed on the whole sequence and then manually adjusted in later stages.
In the last reﬁnement stage, in addition to the gradient-driven model minimization,
rigid-body reﬁnement (where each segment of the ﬁve subunits was considered a
rigid body) and grouped β-factor (ADP) reﬁnement were employed, leading to a
mean β-factor of 40.9 Å (ref. 2). Molprobity was used for structure validation53 and
the EMRinger score54 was calculated for a model comprising all the ﬁve subunits
used in the reﬁnement. Model building and reﬁnement statistics are shown in the
Extended Data Table 2. No Ramachandran outliers were detected and 91.8% of the
residues were found in the favored regions of the Ramachandran plot. The residues
falling in the allowed regions of the Ramachandran plot are Pro14, Thr17, Cys22,
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Ala74, Ser79, and Gly80, which are mostly located at turns or kinks in the poly-
peptide. Secondary structures were analyzed using STRIDE26. Figures were pre-
pared using Pymol, Chimera, and CCP4mg50,55.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The AL55 cryo-EM map has been deposited with the Electron Microscopy Data Bank
(code EMD-0274); the reﬁned molecular model has been deposited in the Protein Data
Bank (code 6HUD). Monoclonal LC sequence was deposited in GenBank database
(accession number MH670901). Other data are available from the corresponding authors
upon reasonable request.
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